• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Evolus Inc.

    3/4/25 4:44:43 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EOLS alert in real time by email
    S-8 1 evoluss-82025.htm S-8 Document

             As filed with the Securities and Exchange Commission on March 4, 2025.

    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ___________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ___________________
    Evolus, Inc.
    (Exact name of registrant as specified in its charter)
    ___________________
    Delaware46-1385614
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification No.)

    520 Newport Center Drive, Suite 1200
    Newport Beach, California 92660
    (Address of Principal Executive Offices) (Zip Code)
    ___________________

    Evolus, Inc. 2017 Omnibus Incentive Plan
    Evolus, Inc. 2023 Inducement Incentive Plan
    (Full title of the plans)
    ___________________

    David Moatazedi
    President and Chief Executive Officer
    Evolus, Inc.
    520 Newport Center Drive, Suite 1200
    Newport Beach, California 92660
    (949) 284-4555
    (Name and address of agent for service) (Telephone number, including area code, of agent for service)
    ___________________
    Copies to:
    Jeffrey J. Plumer
    General Counsel
    Evolus, Inc.
    520 Newport Center Drive, Suite 1200
     Newport Beach, California 92660
    (949) 284-4555

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b–2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☒
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE

    This Registration Statement is filed by the Registrant to register additional securities issuable pursuant to each of (1) the Registrant's 2017 Omnibus Incentive Plan (the “2017 Plan”) and (2) the Registrant's 2023 Inducement Incentive Plan (the “2023 Plan”) and consists of only those items required by General Instruction E to Form S-8.
    PART I

    INFORMATION REQUIRED IN THE
    SECTION 10(a) PROSPECTUS

        The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).

    PART II

    INCORPORATION BY REFERENCE OF CONTENTS OF
    REGISTRATION STATEMENT ON FORM S-8

    Item 3.    Incorporation of Certain Documents by Reference
    The following documents of the Company filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:
    (a)    The Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2024, filed with the Commission on March 4, 2025 (Commission File No. 001-38381);
    (b)    The description of the Company’s Common Stock contained in its Registration Statement on Form 8-A filed with the Commission on February 1, 2018, as modified by the description of the Company’s Common Stock contained in Exhibit 4.3 to the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2023, filed with the Commission on March 7, 2024 (each, Commission File No. 001-38381), and any other amendment or report filed for the purpose of updating such description; and

    (c)    The Company’s Registration Statements on Form S-8 previously filed with the Commission on March 7, 2024 (File No. 333-277754), March 7, 2023 (File No. 333-270360), March 4, 2022 (File No. 333-263325), March 26, 2021 (File No. 333-254746), February 25, 2020 (File No. 333-236620), January 10, 2019 (File No. 333-229184), and February 16, 2018 (File No. 333-223068) relating to the 2017 Plan.
    (d)    The Company's Registration Statement on Form S-8 previously filed with the Commission on October 6, 2023 (File No. 333-274906) relating to the 2023 Plan.
    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.
    Item 5.    Interests of Named Experts and Counsel
    The validity of the issuance of securities registered hereby is passed on for the Company by Jeffrey J. Plumer. Mr. Plumer is General Counsel, of the Company and is compensated by the Company as an employee. Mr. Plumer holds 90,615 shares of Company common stock, 95,863 Company restricted stock units that are payable in an equivalent number of shares of Company common stock, up to 20,520 Company performance restricted stock units that are payable in various numbers of shares of Company common stock depending on achievement of certain



    performance milestones, and Company stock options to acquire up to an additional 379,883 shares of Company common stock. Mr. Plumer is eligible to receive additional stock awards by the Company under the 2017 Plan.
    Item 8.    Exhibits.

    The following exhibits are filed herewith or incorporated by reference as part of this Registration Statement:
    Exhibit No.Description
    4.1
    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on February 12, 2018).
    4.2
    Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated June 12, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on June 14, 2023)
    4.3
    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on February 12, 2018).
    4.4
    Specimen certificate evidencing shares of common stock of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-222478)).
    5*
    Opinion of Counsel (Legality of Shares)
    23.1*
    Consent of independent registered public accounting firm.
    23.2*
    Consent of Counsel (included as part of Exhibit 5).
    24.1*
    Power of Attorney (included on signature page hereto).
    99.1
    2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-222478)).
    99.2
    2023 Inducement Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registrant's Registration Form on Form 8-K (File No. 333-274906)
    99.3*
    First Amendment to the Evolus, Inc. 2023 Inducement Incentive Plan
    107*
    Filing fee table

    *    Filed herewith





    SIGNATURES
        Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newport Beach, State of California, on March 4, 2025.
    EVOLUS, INC.
    /s/ David Moatazedi
    By:David Moatazedi
    President and Chief Executive Officer
        KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Moatazedi and Sandra Beaver and each or either of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8, including any and all post-effective amendments and amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
        Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ David MoatazediPresident, Chief Executive Officer and
    Member of the Board of Directors
    (Principal Executive Officer)
    March 4, 2025
    David Moatazedi
    /s/ Sandra BeaverChief Financial Officer
    (Principal Financial and Accounting Officer)
    March 4, 2025
    Sandra Beaver
    /s/ Vikram MalikChairman of the Board of DirectorsMarch 4, 2025
    Vikram Malik
    /s/ Simone BlankDirectorMarch 4, 2025
    Simone Blank
    /s/ David GillDirectorMarch 4, 2025
    David Gill
    /s/ Karah ParschauerDirectorMarch 4, 2025
    Karah Parschauer



    /s/ Brady StewartDirectorMarch 4, 2025
    Brady Stewart
    /s/ Albert G. White IIIDirectorMarch 4, 2025
    Albert G. White III


    Get the next $EOLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EOLS

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    BTIG Research
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    6/23/2022$18.00Buy
    Needham
    5/12/2022$8.00 → $10.00Underweight → Equal Weight
    Barclays
    1/20/2022$11.00Hold → Buy
    Truist
    11/3/2021$22.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Moatazedi David sold $77,512 worth of shares (6,251 units at $12.40), decreasing direct ownership by 1% to 508,619 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      3/28/25 6:59:18 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Avelar Rui sold $369,868 worth of shares (27,904 units at $13.26), decreasing direct ownership by 7% to 362,467 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      3/20/25 6:27:35 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Beaver Sandra sold $119,243 worth of shares (8,996 units at $13.26), decreasing direct ownership by 5% to 173,583 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      3/20/25 6:27:25 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Evolus with a new price target

      BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus upgraded by Barclays with a new price target

      Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously

      1/29/24 7:09:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Evolus with a new price target

      Needham initiated coverage of Evolus with a rating of Buy and set a new price target of $18.00

      6/23/22 7:38:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evolus Reports First Quarter 2025 Results

      Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

      5/7/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

      Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based on current interest rates. The facility will mature five years from the funding date. Interest will be paid quarterly

      5/5/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus to Report First Quarter Financial Results on May 7, 2025

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (800) 579-2543 (U.S.) or (785) 424-1789 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay

      4/23/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Evolus Inc.

      10-Q - Evolus, Inc. (0001570562) (Filer)

      5/7/25 5:02:48 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Evolus, Inc. (0001570562) (Filer)

      5/7/25 4:07:05 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Evolus, Inc. (0001570562) (Filer)

      5/5/25 4:08:09 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Financials

    Live finance-specific insights

    See more
    • Evolus Reports First Quarter 2025 Results

      Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

      5/7/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus to Report First Quarter Financial Results on May 7, 2025

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (800) 579-2543 (U.S.) or (785) 424-1789 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay

      4/23/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

      Global Net Revenue Record of $79.0 Million for the Fourth Quarter and $266.3 Million for the Full-Year 2024, Representing 30% and 32% Growth Over the Prior Year, Respectively; Results Unchanged from January Preliminary Results GAAP Operating Loss Improved to $2.3 Million for the Fourth Quarter and $34.4 Million for the Full-Year 2024; Second Quarter of Profitability1 with Positive Non-GAAP Operating Income of $6.7 Million for Q4 2024 and Achieved Full-Year Profitability1 One Year Ahead of Expectations with Positive Non-GAAP Operating Income of $0.3 Million for FY 2024; On Track to Expanding Non-GAAP Operating Income Margins and Cash Generation Full-Year 2024 Non-GAAP Operating Expense

      3/4/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:50:28 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:00:06 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/13/24 5:38:05 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

      1/4/24 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

      Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:

      8/21/23 8:45:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care